Headquartered in Bothell, WA Fiscal year ends December NASDAQ: IMNM immunome.com
Immunome, Inc. is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. The company's pipeline includes varegacestat, a gamma secretase inhibitor for desmoid tumors with an NDA accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 antibody-drug conjugate (ADC); IM-1617, a solid tumor ADC incorporating the company's proprietary HC74 TOP1 inhibitor payload; and IM-3050, an FAP-targeted radioligand therapy. Immunome is also advancing a portfolio of early-stage ADCs targeting undisclosed solid tumor antigens. The company trades on Nasdaq under the ticker IMNM. Updated
Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant…
Immunome, Inc. is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies. The company's pipeline includes varegacestat, a gamma secretase inhibitor for desmoid tumors with an NDA accepted by the U.S.
The Wall Street consensus 12-month price target for IMNM is $35.19.
